Skip to main content

news

 

Shardul Amarchand Mangaldas & Co has advised Netherlands-headquartered speciality ingredient solutions provider Barentz International on its acquisition of India-based Anshul Life Sciences, which was represented by AZB & Partners.

Financial terms of the deal were not disclosed, but media sources put it at 170 million euros ($188 million).

The acquisition establishes a life sciences distribution platform for Barentz in India, with expected strategic growth opportunities across the Asia Pacific region. Anshul Life Sciences is a speciality chemical distributor focused on the regulated pharmaceutical, food and nutraceutical, and personal care markets.

The SAM team was led by partners Roopal Kulsrestha, Neelam Pathak, and Meghna Nachappa, and included associates Aparna R, Sandra Anil Varkey, Pranav Bajaj, and Sidharth Chamarthy.

The AZB team included senior partner Vaidhyanadhan Iyer and partner Sneha Nagvekar, along with associates Deepti Narayanan, Priyasha Goyal, Jay Singhee, and Meghna Somani.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.